A series of 21 male breast carcinomas were immunostained using NCL-CB11, an antibody directed against the internal domain of the c-erbB-2 transmembrane oncoprotein. In contrast to female breast cancer, where up to 35% of cases show positivity, all of these cases were negative. This suggests that no prognostic information regarding patient survival can be made in these patients and that male breast carcinomas may be under different growth control mechanisms from female breast carcinomas. We examined a series of these lesions for c-erbB-2 expression using a mouse monoclonal antibody generated against the C-terminal portion of a synthetic peptide sequence of the internal domain (NCL-CB1 1; Novocastra Laboratories, Newcastle) on formalin fixed, paraffin wax embedded tissue. A previous report using this particular antibody on female breast carcinomas showed a high degree of correlation between c-erbB-2 amplification and c-erbB-2 oncoprotein expression.7 Twenty one cases of male breast carcinoma were collected. One tumour was predominantly intraductal with a minor invasive component, the remainder being invasive ductal of no special type, although eight of these had a minor intraductal component. These were immunostained using the mouse monoclonal antibody NCL-CB1 1, using a peroxidase antiperoxidase technique. Endogenous peroxidase was blocked with 0 5% hydrogen peroxide in methanol before pre-treatment with rabbit serum at a 1 in 5 dilution for 15 minutes. The primary antibody was applied at a 1 in 40 dilution and incubated overnight at 4°C before application of rabbit anti-mouse immunoglobulin (Dako) at 1 in 100 for 30 minutes, followed by mouse peroxidase antiperoxidase (Dako) at 1 in 100 for 30 minutes. Peroxidase activity was visualised with diaminobenzidine solution. Omission of the primary antibody for each case was used as a negative control and a known c-erbB-2 positive Paget's disease of breast as a positive control.3 The positive control showed intense membrane staining of tumour cells in the nipple epithelium while no positive staining was identified in any of the sections of male breast carcinomas.
The c-erbB-2 proto-oncogene is located on chromosome 17q21 and encodes an 18-5 kilodalton transmembrane protein of the tyrosine kinase family.' C-erbB-2 shares extensive homology with the epidermal growth factor receptor' and there is various evidence to suggest it too may also behave as a growth factor receptor.23 It is expressed in several types of human tumours including female breast carcinoma' where amplification and c-erbB-2 oncoprotein expression are related to a poor prognosis. 4 Male breast carcinomas, like their female counterparts, are thought to have hormonal influences in their aetiology. Associations with endocrine disease, hormone treatment, and altered oestrogen metabolism have been described.56 These similarities between breast carcinomas of men and women warrant comparative investigations, not only to improve our understanding of this disease in men, but also to pinpoint distinctive features of female breast carcinoma. Studies in male breast carcinoma are few, however, due to the rarity of the disease. Indeed, we have been unable to identify any published data on oncoproteins in male breast carcinoma that are now known to be important in female breast carcinoma. Therefore, this study was undertaken to determine the frequency and distribution of the expression of one such oncoprotein, c-erbB-2, in male breast carcinomas and to evaluate any similarities with or differences from female breast cancers.
We examined a series of these lesions for c-erbB-2 expression using a mouse monoclonal antibody generated against the C-terminal portion of a synthetic peptide sequence of the internal domain (NCL-CB1 1; Novocastra Laboratories, Newcastle) on formalin fixed, paraffin wax embedded tissue. A previous report using this particular antibody on female breast carcinomas showed a high degree of correlation between c-erbB-2 amplification and c-erbB-2 oncoprotein expression.7 Twenty one cases of male breast carcinoma were collected. One tumour was predominantly intraductal with a minor invasive component, the remainder being invasive ductal of no special type, although eight of these had a minor intraductal component. These were immunostained using the mouse monoclonal antibody NCL-CB1 1, using a peroxidase antiperoxidase technique. Endogenous peroxidase was blocked with 0 5% hydrogen peroxide in methanol before pre-treatment with rabbit serum at a 1 in 5 dilution for 15 minutes. The primary antibody was applied at a 1 in 40 dilution and incubated overnight at 4°C before application of rabbit anti-mouse immunoglobulin (Dako) at 1 in 100 for 30 minutes, followed by mouse peroxidase antiperoxidase (Dako) at 1 in 100 for 30 minutes. Peroxidase activity was visualised with diaminobenzidine solution. Omission of the primary antibody for each case was used as a negative control and a known c-erbB-2 positive Paget's disease of breast as a positive control.3 The positive control showed intense membrane staining of tumour cells in the nipple epithelium while no positive staining was identified in any of the sections of male breast carcinomas.
This study of a relatively large number of male breast carcinomas shows that, in contrast to female breast carcinomas which show up to 35% positivity,' no significant c-erbB-2 expression is present and therefore amplification improbable. Thus unlike female breast carcinomas, no conclusion regarding its role as an independent negative predictor of prognosis can be made. As survival is little different between male and female breast carcinomas,6 similar expression of c-erbB-2 might have been expected, but these results suggest that other factors may be involved in the transformation and growth of male breast carcinomas.
We thank Dr PA Burton, Southmead Hospital, Bristol for supplying several cases. In most populations the prevalence of tuberous sclerosis has been estimated to be about one in 100 000, but there are considerable regional differences (one in 20 000 to one in 300 000).' The basic metabolic mechanism underlying the disease remains unknown. Diagnosis can be made in utero.
Epilepsy, the most common clinical manifestation, is often present from early childhood, but not always. Mental retardation is found in about half the patients.
Sebaceous adenomas or cutaneous fibroangiomas are diagnostic and are found in up to 90% of the cases. The appearance varies and the most frequently affected areas are the nose, the chin, and the forehead. Hypopigmented areas are often a concomitant feature.
The central nervous system abnormalities in tuberous sclerosis are characterised by calcified subependymal and cortical nodules (tubers 
